

## QIBA FDG-PET/CT Tech Ctte Update Call

13 July 2012 at 9 AM CT (GMT-5)

Draft Call Summary

### In attendance:

**Ling X. Shao, PhD (co-chair)**

**Richard L. Wahl, MD (co-chair)**

Keith Allberg

Andrew Buckler, MS

Barbara Croft, MD

Howard Higley, PhD

John Hoffman, MD

Martin Lodge, PhD

Lawrence MacDonald, PhD

Eric Perlman, MD

Anne Smith, PhD

Rathan Subramaniam, MD

John Sunderland, PhD

Valerie Treyer, PhD

Timothy Turkington, PhD

Scott Wollenweber, PhD

John Wolodzko, PhD

Brian Zimmerman, PhD

**RSNA**

Julie Lisiecki

Madeleine McCoy

### Discussion

- Group reviewed Dr. Lodge's draft version of the claim with Dr. Higley's suggested edits.
- Revised *draft* wording per group discussion:
  - Claim: Tumor glycolytic activity as reflected by the maximum standardized uptake value (SUVmax ) can be measured from FDG-PET/CT within a (within-patient) coefficient of variation of 12% with the same scanner at single center
  - These data imply a coefficient of repeatability of 33%, i.e. separate SUVmax measurements derived from test-retest PET/CT studies will differ by less than 33% for 95% of observations.
- Suggested structure for wording of claim: *If abc Profile details are met, then xyz results are expected...*
  - Wording and structure of claim must be consistent with Profile structure.
- Focusing on relative change – goal is to achieve the same “change” if protocols are implemented at different sites.

### Assignments

- Dr. Wolodzko to prepare a list of pros and cons for three different phantoms for the next call
- Dr. Perlman to be asked to review consistency of definitions language and develop a strategy to share information across QIBA Tech Cttes for future Profiles
- Drs. Lodge and Hoekstra to provide text for sections 6.4 and 6.5
- Dr. Yap is reviewing the Appendix
- Dr. Kinahan is reviewing the common data format mechanism relating to DICOM details as well as recalibration and change of measurements up to 10%
- Dr. Cole will email list of acronyms to Dr. Kinahan
- New action item: If targeting mid-August for Profile completion, FDA briefing document needs to be ready at same time

### Next steps:

- Approach to addressing Public Comment needs further discussion

**Next call:** To continue discussion of the Draft Claim at **9 am (CT) July 20<sup>th</sup>**.